EU/3/20/2317

About

On 21 August 2020, orphan designation EU/3/20/2317 was granted by the European Commission to Smart Immune, France, for allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured (also known as HTLPs) for treatment in haematopoietic stem cell transplantation.

Key facts

Active substance
Allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured
Disease / condition
Treatment in haematopoietic stem cell transplantation
Date of first decision
21/08/2020
Outcome
Positive
EU designation number
EU/3/20/2317

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Eligo Bioscience
Pepiniere Sante Cochin
29 Rue Du Faubourg Saint Jacques
75014 Paris
France
Tel: +33 (0)9 62 50 19 97
E-mail: contact@eligo-bioscience.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating